Early Malnutrition Detection in Leukemia Patients Using Bioimpedance

Introduction

Malnutrition is a significant concern in patients with acute leukemia, often going unrecognized at the time of diagnosis. Traditional nutritional screening methods, primarily based on anthropometry, frequently fail to detect early nutritional decline. A study published in Nutrients aimed to evaluate whether a comprehensive morphofunctional assessment, including bioelectrical impedance vector analysis (BIVA), handgrip strength (HGS), and muscle ultrasound, could improve the early identification of nutritional risk and predict mortality in these patients.

The Study in Detail

The study, titled "Bioelectrical Impedance and GLIM Criteria Identify Early Nutritional Deterioration and Mortality in Acute Leukemia Patients Undergoing Chemotherapy," was conducted by Dalla Rovere L. et al. and published in Nutrients (2026 Jan 23;18(3):374). The research involved a prospective cohort of 52 adult patients newly diagnosed with acute leukemia, enrolled between November 2022 and November 2024 at two tertiary hospitals in Málaga, Spain.

Nutritional status was determined using the Global Leadership Initiative on Malnutrition (GLIM) criteria. A comprehensive morphofunctional assessment was performed at diagnosis and again after induction therapy. This assessment included:

• Bioelectrical Impedance Vector Analysis (BIVA): Specifically, the phase angle (PhA) derived from BIVA.
• Handgrip Strength (HGS): Measured via dynamometry.
• Muscle Ultrasound: Focusing on the rectus femoris cross-sectional area.

The primary outcome measured was 12-month mortality. Statistical analyses, including logistic regression and ROC analysis, were used to assess prognostic associations.

Key Findings:

• At baseline, 65.4% of patients were classified as malnourished according to GLIM criteria.
• After three months of treatment, significant declines were observed in several parameters: PhA (-0.55°, p < 0.001), body cell mass (-3.15 kg, p < 0.01), skeletal muscle mass (-1.66 kg, p < 0.01), and rectus femoris cross-sectional area (-0.36 cm², p = 0.011).
• Baseline malnutrition (Odds Ratio [OR] = 6.88; 95% Confidence Interval [CI]: 1.17-40.38; p = 0.033) was independently associated with higher 12-month mortality.
• A decline in PhA of ≥ 0.90° during treatment was also independently associated with higher 12-month mortality.

Assessment

This study provides valuable insights into the early identification of nutritional risk in acute leukemia patients. The findings underscore the limitations of traditional anthropometric methods and highlight the utility of more advanced morphofunctional assessments. The use of GLIM criteria, combined with objective measures like BIVA-derived phase angle and muscle ultrasound, offers a more sensitive approach to detecting nutritional deterioration.

The significant decline in markers such as phase angle, body cell mass, and skeletal muscle mass within three months of treatment indicates a rapid and substantial impact of chemotherapy on nutritional status. The independent association of baseline malnutrition and a decline in phase angle with increased 12-month mortality suggests these markers are not only indicators of nutritional status but also strong prognostic factors for patient outcomes.

Strengths of the study include:

• Its prospective cohort design.
• The comprehensive nature of the morphofunctional assessment, combining multiple objective measures.
• The focus on a high-risk patient population where early intervention is crucial.

Limitations to consider:

• The relatively small sample size (n=52), which may limit the generalizability of the findings.
• The study was conducted at two tertiary hospitals in a specific geographical region, which might influence patient characteristics and treatment protocols.
• While the associations are significant, further research with larger and more diverse cohorts would strengthen these conclusions.

Practical Relevance

The results of this study have concrete implications for the nutritional management of acute leukemia patients. Given that traditional screening tools often miss early nutritional decline, integrating comprehensive morphofunctional assessments into routine clinical practice could significantly improve patient care. Specifically, the use of GLIM criteria alongside BIVA and muscle ultrasound at diagnosis and during early treatment phases could help identify patients at high nutritional and functional risk.

For individuals undergoing chemotherapy for acute leukemia, monitoring parameters like the phase angle from BIVA could serve as an early warning sign for impending nutritional deterioration. A decline in phase angle of 0.90° or more appears to be a critical threshold associated with increased mortality risk. This emphasizes the need for proactive and personalized nutritional interventions, rather than waiting for overt signs of severe malnutrition.

From a nutritional science perspective, this research reinforces the importance of preserving body cell mass and skeletal muscle mass during catabolic states induced by disease and treatment. Early and targeted nutritional support, possibly including specific dietary modifications or supplementation, could potentially mitigate these declines and improve overall patient outcomes.

Conclusion

This study highlights the critical role of early and comprehensive morphofunctional assessment, including GLIM criteria, BIVA, and muscle ultrasound, in identifying nutritional and functional risk in acute leukemia patients. The findings demonstrate that baseline malnutrition and a significant decline in phase angle during treatment are independently associated with higher 12-month mortality. These results advocate for the implementation of early, personalized nutritional interventions to improve the prognosis and quality of life for patients undergoing chemotherapy for acute leukemia.